• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Latest News

Daily Derm Times: June 16, 2025
Daily Derm Times: June 16, 2025

June 17th 2025

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Q&A: Peter Lio, MD, on Safety in Pediatric AD Management and the Promise of Precision Medicine
Q&A: Peter Lio, MD, on Safety in Pediatric AD Management and the Promise of Precision Medicine

June 16th 2025

A Clinician’s Perspective of RAD 2025: Part 2
A Clinician’s Perspective of RAD 2025: Part 2

June 16th 2025

SLIDESHOW: Recent Data from LEO Pharma on Chronic Hand Eczema
SLIDESHOW: Recent Data from LEO Pharma on Chronic Hand Eczema

June 16th 2025

Nearly Half of Patients Respond to Ritlecitinib for Alopecia Areata, With Most Sustaining Results
Nearly Half of Patients Respond to Ritlecitinib for Alopecia Areata, With Most Sustaining Results

June 16th 2025

Introducing Dermatology Times' 2025 Editor in Chief
Explore Emerging Treatments and Clinical Tools for CHE
Subscribe Now for Free - eNL
Explore Our Conference Coverage
Subscribe for Free - Print
Advancing AD Treatment: Expert-Led Case Discussions
Breaking Down New Treatment Options in Pediatric Atopic Dermatitis
Stay Informed!
Don't miss the latest in dermatology news
Managing Prurigo Nodularis

Conference Coverage

View All
Q&A: Peter Lio, MD, on Safety in Pediatric AD Management and the Promise of Precision Medicine
Q&A: Peter Lio, MD, on Safety in Pediatric AD Management and the Promise of Precision Medicine

June 16th 2025

A Clinician’s Perspective of RAD 2025: Part 2
A Clinician’s Perspective of RAD 2025: Part 2

June 16th 2025

Looking Ahead to Povorcitininb for HS and the Availability of Generic Tofacitinib
Looking Ahead to Povorcitininb for HS and the Availability of Generic Tofacitinib

June 13th 2025

A Clinician’s Perspective of RAD 2025: Part 1
A Clinician’s Perspective of RAD 2025: Part 1

June 12th 2025

Latest Videos

All News

© 2025 MJH Life Sciences

All rights reserved.